The effectiveness of targeted therapy with bevacizumab combined with chemotherapy for metastatic colorectal cancer-Reference-Cited by-同舟云学术

The effectiveness of targeted therapy with bevacizumab combined with chemotherapy for metastatic colorectal cancer

Published:2020-12-28 Issue:4 Volume: Page:55-58
ISSN:1609-1175
Container-title:Pacific Medical Journal
language:
Short-container-title:Tihookeanskij medicinskij žurnal

Author:

Ovodova A. V.¹^ORCID,Petukhova Yu. Yu.²,Eliseeva E. V.¹,Perelomova O. V.¹

Affiliation:

1. Pacific State Medical University

2. Pacific State Medical University; Primorskiy Regional Oncological Dispensary

Abstract

Objective: To estimate the effectiveness of the target therapy with bevacizumab combined with chemotherapy for metastatic colorectal cancer.Methods: Life expectancy of 208 patients having 3rd and 4th stages was retrospectively analyzed. They received different kinds of treatment: FOLFOX, canecitabin with FOLFOX combined with bevacizumab.Results: Average life expectancy of the patients having 3rd stage of colorectal cancer is 11.4 months of those who applied FOLFOX scheme, and 14.4 months taking “FOLFOX+bevacizumab” scheme. Of those patients having the 4th stage of cancer this combination of chemotherapy and target medicine resulted in an increase in life expectancy for 3.7 months.Conclusions: Inclusion of bevacizumab in treatment plan of the patients having 3rd and 4th stages of colorectal cancer improves life expectancy indexes of the patients.

Publisher

Pacific State Medical University

Subject

General Medicine

Reference15 articles.

1. World Health Organization. International Agency for Research on Cancer 2019. GLOBOCAN 2018: Estimated cancer incidence, mortality, and prevalence worldwide in 2018. Cancer fact sheets. URL: https://gco.iarc.fr/today/home (Accessed: 1 June 2019).

2. Sobolevskaya OA, Ponomarev AF, Gavrina SE, Denisenko LS, Shkuratova OK, Rogatkina ES, Ivanov SP. Colorectal cancer in the Primorsky Territory: Problems of diagnosis and treatment. Pacific Medical Journal. 2013;3:80–2 (in Russ).

3. Fedorov VE, Podelyakin KA. Epidemiological aspects of colorectal cancer (review). Medical Almanac. 2017;4:145–6 (in Russ).

4. Khaitov RM, Kadagidze ZG. Immunity and cancer. Moscow: GEOTAR-Media; 2018:139–46 (in Russ.).

5. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.